

# Aerocrine

Press release  
8 April, 2008

## **Airway inflammation measurement receives reimbursement in Czech Republic**

**SOLNA, Sweden – 8 April, 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced that a new reimbursement code has been issued for the exhaled NO tests in the Czech healthcare system.**

Healthcare providers using exhaled Nitric Oxide (NO) to measure airway inflammation, the root cause of asthma, will receive payment of €13.50 per test from April 2008. The reimbursement (code 27270) allows physicians to use exhaled NO tests to more accurately diagnose patients with asthma and to better control their asthma symptoms.

The use of anti-inflammatory therapy, such as inhaled corticosteroids, forms a cornerstone in asthma treatment. Inflammation monitoring made possible by exhaled nitric oxide measurements allows care providers to predict drug response. The test can also be used to monitor the effects of treatment and to adjust to the correct dose. A rise in the exhaled NO value may indicate that the patient is not adhering to the prescribed anti-inflammatory treatment or that the disease is worsening. By regular monitoring of airway inflammation through exhaled NO measurements, the management and care of asthma patients may be dramatically improved, which in turn leads to more cost effective treatment.

Aerocrine's NIOX MINO<sup>®</sup> Airway Inflammation Monitor permits non-invasive, quick and easy-to-perform eNO measurements.

For more information, contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 82

### **About Aerocrine**

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX<sup>®</sup> Flex and NIOX MINO<sup>®</sup>. Both products enable fast and reliable measurement of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June, 2007.

Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act. The information was submitted for publication at 8 am on 8 April, 2008.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------